



Acute myeloid leukemia (AML) is a heterogeneous hematologic 
malignancy characterized by the clonal expansion of myeloid blasts 
in the peripheral blood, bone marrow, and/or other tissues, with 
maturation arrest of cells in the bone marrow and impaired production 
of normal blood cells [1, 2].
Treatment strategies of patients with AML are based on various 
prognostic factors, including age and performance status of the 
patient, as well as cytogenetic and molecular characteristics of the 
leukemic clone [3].
To date, cytogenetic abnormalities have provided the most prognostic 
information [4]. However, 40%-49% of adult AML patients have 
a cytogenetically normal (CN) phenotype, which would make 
additional prognostic factors particularly useful in this group [5, 6].
Cluster of differentiation (CD)-25 represents the a-chain of the 
interleukin-2 receptor (IL-2Ra), a low-affinity binding receptor [7]. 
The IL-2 receptor is composed of different combinations of three 
subunits (alpha, beta, and gamma chains) and is normally expressed 
on activated T-cells. Upon binding its ligand IL-2, the IL-2 receptor 
induces T-cell proliferation and differentiation [8].
Recent research has described CD25 as a poor prognostic factor 
in acute lymphoblastic leukemia [9]. Moreover, in AML, previously 
published data from small retrospective studies have suggested an 
unfavorable impact of CD25 [10, 11].
Therefore, our aim was to evaluate the expression of CD25 in adult 
Egyptian patients with newly diagnosed AML and thereafter study its 
impact on prognosis.
Subjects and methods
The current study was conducted with 50 newly diagnosed adult AML 
patients before receiving induction chemotherapy. All patients were 
presented to the Hematology Department of the Alexandria Main 
University Hospital. Complete blood count (CBC) was determined and 
bone marrow (BM) aspirate was obtained on initial diagnosis and 28 days 
after receiving induction chemotherapy to follow up their response to 
treatment (complete remission [CR] or relapse), and we evaluated the 
survival for 18 months. All our patients received induction treatment. 
The treatment was the 3+7 protocol, which consisted of daunorubicin at 
45 mg/m2 for 3 days + cytarabine at 100 mg/m2 by continuous infusion for 
7 days (the standard 3+7 induction protocol) [12, 13].
All our participant patients provided informed consent, and the study 
was approved by the Ethics Committee of Alexandria University, 
Faculty of Medicine.
All patients were subjected to full history taking, thorough clinical 
examination, and laboratory investigations, including the following: 
Peripheral blood sampling for CBC determination was performed 
on ADVIA 2120i automated blood cell counter (Siemens Healthcare 
Diagnostics, USA); BM aspiration and immunophenotyping were 
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performed using Becton Dickinson, FACSCalibur flow cytometer 
equipped with Cell Quest software (USA) [14–16].
Immunophenotyping analysis
The detailed characterization of hematopoietic cells was done 
by analyzing the expression of a given set of antigens in a cell 
population. The applied panels of monoclonal antibodies (McAbs) 
for diagnosis of acute leukemia were as follows: primary panel: CD2 
– phycoerythrin (PE); CD5 – PE; CD7 – fluorescein isothiocyanate 
(FITC); CD10 – FITC; CD19 – R-phycoerythrin (RPE); CD14 – FITC; 
CD13 – PE; CD33 – PE; HLA-Dr – FITC; CD34 – FITC; and CD45 – 
FITC; confirmatory antibodies: cytoplasmic (Cyt) CD22 – FITC; Cyt 
IgM – PE; Cyt CD3 – FITC; and Cyt anti-myeloperoxidase (MPO) 
– FITC).
For CD25 analysis, the stain/lyse/wash technique was applied. 
Briefly, 10 μl of the CD25-PE McAb (clone: TP1/6, cat. ref: 25PE-
100T, HT-PE-0025-1, Immunostep, Spain) was added to 100 μl 
of ethylenediaminetetraacetic acid (EDTA) BM, mixed well, and 
incubated for 10 minutes at room temperature. The cells were then 
washed twice with phosphate-buffered saline (PBS); 2 ml lysing 
solution was added, mixed, and left for 10 minutes in the dark, and 
then the cells were washed twice with PBS. After the last wash, the 
cells were analyzed using a flow cytometer. During analysis, a gate 
was set around the required blast population. The cutoff point of 
positivity was considered when > 20% of the cells were stained with 
a particular antibody in  excess of the background fluorescence in 
the negative controls. We used the cutoff value 20% according to the 
established flow cytometry protocol in the flow cytometry unit of our 
department.
Cytogenetic study
This study was done on 11 patients only because of the small sample 
size or bad metaphase quality, which was inadequate for karyotyping 
analysis in the remaining cases [17–19].
Chromosomes were prepared from dividing cells (mitotic cells).Cells 
were cultured in RPMI 1640 (cat. number: L0496-500, France), 
supplemented with fetal bovine serum (lot number: 0522D, Germany), 
L-glutamine (lot number: 1223D, Germany), as well as penicillin and 
streptomycin (cat. number: ECB3001D, Italy).
Cell division was halted at the metaphase, since, at this stage, the 
chromosomes condense and become recognizable as discrete 
units. This was achieved by destroying the cellular spindle using 
a metabolic inhibitor (colchicine).
The cells were treated with a hypotonic solution to encourage cell 
swelling and spreading of the chromosomes within the cells. They 
were then fixed and stained with Giemsa. This assists in chromosome 
banding (G-banding), and then metaphases were analyzed using the 
Cytovision Applied Imaging System (UK) with Olympus microscope 
CX41RF (S/N: 0L34790, Japan) equipped with camera ER3339 (S/N: 
400561, Japan).
Data were fed into the computer and analyzed using IBM SPSS 
software package version 20.0 for statistical analysis.




Our group of AML patients consisted of 26 males (52%) and 
24 females (48%). Their ages ranged from 14 to 82 years, with 
a mean of 41.2 years; only three patients were above 60 years of 
age. Demographic, clinical, and laboratory data are presented in 
table I. Our diagnosis was based on morphology, BM aspiration, and 
immunophenotyping. No other molecular markers were investigated 
in our study because of financial constraints.
Positive CD25 expression was found in 12 cases (24%) in our 
studied group (Fig. 1). Karyotyping was successfully done in 11 cases 
because of the inadequacy of the samples or bad quality of the 
metaphases in the remaining samples. According to the Medical 
Research Council (MRC) classification, eight cases were of 
intermediate risk having normal karyotypes, while the remaining 
three were of unfavorable risk. No favorable karyotype was detected. 
The response of our patients was highly variable: 32 patients (64%) 
achieved CR from the first induction treatment and were doing well 
until the end of the study; three patients (6%) had a relapse 
after achieving CR; and 15 patients died (seven were nonresponders 
and died of acute respiratory distress syndrome (ARDS) and 
intracranial hemorrhage; three died during their first induction 
treatment from septicemia; and five died in the consolidation phase 
from sepsis or intracranial hemorrhage). None of our patients had 
BM transplantation.
On comparing CD25-positive and -negative patients in terms of the 
demographic data, clinical findings, CBC results, and karyotyping, no 
statistically significant difference was found (Tab. I, Fig. 2).
We tried to study the relation between CD25 expression and outcome 
and found that the CD25-positive group had significantly higher 
relapse and death rates (P = 0.011 and P = 0.027, respectively), apart 
from significantly lower remission rates (P < 0.001).
On combining the karyotype results with those of CD25 expression, 
CD25-positive AML patients with normal karyotype had a significantly 
lower remission rate and significantly higher relapse and death rates 
when compared with CD25-negative patients with normal karyotype 
(P = 0.025). Thus, CD25 added a significant prognostic value to 
the patients with intermediate cytogenetic risk (normal karyotype) 
(Tab. II).
Overall survival (OS) and leukemia-free survival (LFS) were studied 
in relation to age and CD25 expression. CD25-positive patients were 
associated with significantly worse OS (P = 0.008) (Fig. 3 A), shorter 
LFS (P < 0.001) (Fig. 3 B), and lower mean survival (7.9 months) in 
comparison with CD25-negative patients (14.4 months).
No significant differences between the age groups below and above 
60 years in terms of OS(P = 0.084) and LFS (P = 0.130) were 
found (Fig. 4).
We used the age, sex, white blood cell (WBC) count, hemoglobin 
concentration, platelet count, karyotype, percentage of blasts in the 
peripheral blood and BM, CD34 expression on the blast cells, 
and CD25 expression on the blast cells in our univariate analysis 
and then in the multivariate analysis against the outcome. In the 
univariate analysis, CD25 positivity was a strong predictor for bad 
outcome and worse prognosis (P < 0.001). In the multivariate analysis, 
CD25 positivity was the most powerful independent predictor for bad 
prognosis (P = 0.002).
Discussion
A variety of cytokines or ILs have been demonstrated to regulate the 
growth, survival, differentiation, and apoptosis of leukemic cells in 
vitro and in vivo [20, 21]. Cytokines bind to their respective receptors 
on the cell surface to exert their effect. However, little is known about 
the expression of cytokine receptors on the cell surface in AML and 
their clinical relevance [22].
A few researchers have suggested an unfavorable impact of CD25 
expression in AML [10]. Furthermore, CD25-positive AML cells 
were shown to comprise a population of cell cycle-quiescent 
Fig. 2. Male karyotype showing a clone with a deletion of chromosome 5q (q31;q35)
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Table I. Comparison between CD25-negative and -positive patients according to different demographic, clinical, and laboratory 
parameters
Total (n = 50)
CD25
Test of significance P
Negative (n = 38) Positive (n = 12)
Sex
Male 26 (52%) 17 (44.7%) 9 (75%)  c2 = 3.346 0.067
Female 24 (48%) 21 (55.3%) 3 (25%)
Age (years) 45 (14-82) 45 (14-75) 42 (20-82) U = 200.0 0.524
< 60 47 (94%) 37 (97.4%) 10 (83.3%)  c2 = 3.185 0.139
≥ 60 3 (6%) 1 (2.6%) 2 (16.7%)
Fever
No 30 (60%) 22 (57.9%) 8 (66.7%)  c2 = 0.292 0.740
Present 20 (40%) 16 (42.1%) 4 (33.3%)
Fatigue
No – 0 (0.0%) 0 (0.0%) – –
Present 50 (100%) 38 (100.0%) 12 (100.0%)
Bony aches
No 24 (48%) 21 (55.3%) 3 (25%)  c2 = 3.346 0.067
Present 26 (52%) 17 (44.7%) 9 (75%)
Pallor
No 6 (12%) 4 (10.5%) 2 (16.7%)  c2 = 0.326 0.621
Present 44 (88%) 34 (89.5%) 10 (83.3%)
Bleeding
No 38 (76%) 30 (78.9%) 8 (66.7%)  c2 = 0.754 0.448
Present 12 (24%) 8 (21.1%) 4 (33.3%)
Weight loss
No 39 (78%) 29 (76.3%) 10 (83.3%)  c2 = 0.262 1.000
Present 11 (22%) 9 (23.7%) 2 (16.7%)
Lymphadenopathy
No 48 (96%) 36 (94.7%) 12 (100%) 0.658 1.000
Present 2 (4%) 2 (5.3%) 0 (0.0%)
Splenomegaly
No 36 (72%) 27 (71.1%) 9 (75%)  c2 = 0.070 1.000
Present 14 (28%) 11 (28.9%) 3 (25%)
Hepatomegaly
No 41 (82%) 31 (81.6%) 10 (83.3%)  c2 = 0.019 1.000
Present 9 (18%) 7 (18.4%) 2 (16.7%)
WBCs (x109/L) 43.9 (2-503) 43.9 (2-503) 52.5 (2-380) U = 195.50 0.460
Platelets (x109/L) 36.5 (9-313) 36.5 (9-166) 35.5 (10-313) U = 204.50 0.593
Hb (g/dl) 7.9 ± 1.5 7.7 ± 1.3 8.5 ± 1.7 t = 1.655 0.104
Peripheral blood blasts (%) 47 (8-92) 44.5 (8-90) 54 (28-92) U = 190.00 0.388
BM aspirate blasts (%) 64 (22-98) 67 (22-98) 57.5 (29-92) U = 197.0 0.481
FAB
M0 1 (2%) 1 (2.6%) 0 (0.0%)  c2  = 5.740 0.305
M1 5 (10%) 5 (13.2%) 0 (0.0%)
M2 8 (16%) 5 (13.2%) 3 (25%)
M4 23 (46%) 15 (39.5%) 8 (66.7%)
M5a 12 (24%) 11 (28.9%) 1 (8.3%)
M5b 1 (2%) 1 (2.6%) 0 (0.0%)
CD34
Negative 12 (24%) 10 (26.3%) 2 (16.7%)  c2 = 0.466 0.705
Positive 38 (76%) 28 (73.7%) 10 (83.3%)
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Total (n = 50)
CD25
Test of significance P
Negative (n = 38) Positive (n = 12)
Response
Death 15 (30%) 8 (21.1%) 7 (58.3%)  c2 = 17.460* < 0.001*
Relapse 3 (6%) 0 (0.0%) 3 (25%)
Remission 32 (64%) 30 (78.9%) 2 (16.7%)
Prognosis
Good 32 (64%) 30 (78.9%) 2 (16.7%)  c2 = 15.354* < 0.001*
Bad 18 (36%) 8 (21.1%) 10 (83.3%)
Karyotyping: (MRC classification)
Intermediate risk (normal) 8 (72.7%) 5 (62.5%) 3 (100%)  c2 = 1.547 0.234
Unfavorable risk 3 (27.3%) 3 (37.5%) 0 (0.0%)
 c
2
, P:  c
2 and P values for chi-square test for comparing between the two groups.
U, p: U and P values for Mann–Whitney test for comparing between the two groups.
t, p: t and P values for Student’s t-test for comparing between the two groups.
*: Statistically significant at P ≤ 0.05.
Table II. Relation between karyotyping/CD25 and outcome
Response





Intermediate risk (normal) with CD25 +ve 2 (66.7%) 1 (100.0%) 0 (0.0%) 8.106* 0.025*
Intermediate risk (normal) with CD25 –ve 0 (0.0%) 0 (0.0%) 5 (71.4%)
Unfavorable risk (abnormal) with CD25 +ve 0 (0.0%) 0 (0.0%) 0 (0.0%)
Unfavorable risk (abnormal) with CD25 –ve 1 (33.3%) 0 (0.0%) 2 (28.6%)
 c
2
, P:  c
2 and P values for chi-square test for comparing between the two groups.
*: Statistically significant at P ≤ 0.05.




and chemotherapy-resistant leukemia stem cells (LSCs) [23], which 
requires newer therapeutic approaches targeting IL-2Ra to improve 
the prognosis of this type of AML.
Therefore, we aimed to evaluate CD25 expression in 50 newly 
diagnosed adult Egyptian patients with de novo AML, who were 
treated by the standard ‘’3+7’’ protocol, correlate its expression 
with the biological characteristics of the disease and the clinical 
response, as well as assess its prognostic value, especially in the 
largest cytogenetic subclass of AML (those patients with a normal 
karyotype and patients with prognostically noninformative cytogenetic 
aberrations). We found that 24% of our patients had CD25-positive 
blasts at diagnosis.
Gonen et al [24] reported that 13% (87/657) of their AML patients 
had CD25-positive AML, while Fujiwara et al [25] demonstrated 
CD25-positive blasts in 14% (21/154) of de novo AML patients.
Gonen et al [24] and Nakase et al [26] demonstrated in their studies 
that CD25-positive AML patients presented with significantly higher 
WBCs (P < 0.0001 and P = 0.00006, respectively), which was not 
found in the current study (P = 0.46); similar to our findings, Terwijn et 
al [10] failed to find significant correlation between the percentage of 
CD25-positive blasts and WBC count at diagnosis (P = 0.60).
Cytogenetic analysis was done by Gonen et al [24] in all his AML 
patients, and the cytogenetic abnormalities were defined according 
to published criteria [27]. The study reported that distribution of 
cytogenetic risk classes differed significantly between CD25-positive 
and -negative patients (P < 0.0001); moreover, CD25-positive patients 
were mostly in the cytogenetically intermediate-risk group (92%). 
His findings were against ours, as we did not find any significant 
difference between both groups (P = 0.234) in having normal and 
abnormal karyotypes at presentation, which may be due to the small 
sample size of our study group and the fact that karyotyping was 
done in 11 cases only.
Similar to our findings, Cerny et al [28] did not detect any statistically 
significant difference in having normal and abnormal karyotypes 
and in the distribution of cytogenetic risk classes when comparing 
CD25-positive and -negative patients.
 We investigated the effect of CD25 expression in AML patients on the 
clinical outcome; our results showed that CD25-positive AML patients 
with normal karyotype had significantly higher relapse and death 
rates and lower CR rate when compared with the CD25-negative 
patients with normal karyotype (P = 0.025). Moreover, CD25-positive 
patients were associated with worse OS and a significantly shorter 
LFS when compared to the CD25-negative patients.
Similarly, Terwijn et al [10] reported that CD25 expression on 
myeloblasts in AML patients was a valuable prognostic marker within 
the cytogenetically intermediate-risk group and CD25 positivity was 
associated with significantly decreased median OS of 10 months 
versus > 48 months in the CD25-negative group (P = 0.0017). The 
LFS in CD25-positive patients was 6 months versus > 47 months in 
the CD25-negative AML group. Our results were also in agreement 
with those of Cerny et al [28], Nakase et al [26], and Gӧnen et al 
[24], with Gӧnen et al [24] stating that CD25 expression was strongly 
associated with adverse outcome in the cytogenetically intermediate- 
risk patients.
From our results, we concluded that CD25 expression in intermediate- 
risk AML patients was significantly associated with adverse outcome. 
These data revealed that those patients had a greater likelihood of 
harboring unfavorable-risk mutations compared with CD25-negative 
cytogenetically intermediate-risk patients.
All studies, including the present study, consistently showed that the 
expression of CD25 in AML patients at presentation independently 
predicts poor prognosis. Moreover, some studies indicated target 
therapy for CD25-positive  AML other than conventional chemotherapy 
to improve the prognosis of those patients.
Conclusions
Expression of CD25 in AML patients at presentation was associated 
with shorter OS and LFS.
CD25-positive AML patients who had normal karyotype at presentation 
showed lower remission rate and higher relapse and death rates 
when compared with patients who had abnormal karyotype.





Further studies need to be performed on CD25-positive AML patients 
on a wider scale to study other factors that might influence the results 
of chemotherapy treatment as well as to investigate other treatment 
strategies for CD25-positive AML.
Since the detection of CD25 is relatively straightforward and fast, 
we recommend that immunophenotypic detection of CD25 should 
be considered as a part of the routine workup of AML patients 
with normal karyotype, since it helps dissecting this heterogeneous 
cytogenetic category into prognostically different subgroups.
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